Trial Profile
A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 May 2017
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 28 Apr 2017 Results published in the Bristol Myers Squibb Media Release
- 03 Mar 2017 Status changed from active, no longer recruiting to completed.
- 25 Apr 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Aug 2016.